Every AI newsletter,Huafu Securities issued a research report on September 2 stating that it maintains Huaxi Biological (688363.SH, latest price: 175.33 yuan) prudential recommendation rating. The reasons for the rating mainly include: 1) In 2021 H1, the company realized operating income of 1.937 billion yuan, an increase of 104.44%. The company’s functional skin care business has the highest proportion and the fastest growth rate. The four major brands have achieved high growth rates, and the bioactive raw materials in the raw material business have performed well; 2)In 2021H1, the net profit will be about 360 million yuan, an increase of 34.93%; the net profit attributable to the parent will be 361 million yuan, an increase of 35.01%. If the impact of share-based payment is excluded, the net profit attributable to the parent will be 397 million yuan, an increase of 48.65%; 3)Online promotion has been intensified, sales expenses have increased significantly, and the number of R&D projects has increased by 63.72%.724 new intellectual property rights were added. Affected by the adjustment of freight-related accounting standards, operating costs have increased, and the company’s gross profit margin for 2021H1 was 77.91%, a decrease of 1.83pct.Risk warning: intensified industry competition, increased difficulty in online promotion, and new product research and development that fell short of expectations.
AI comment: Huaxi Biotechnology has received 19 securities research reports in the past month, bought 12 companies and increased holdings of 3 companies. The average target price is 276.79 yuan, which is 101.46 yuan higher than the latest price of 175.33 yuan, and the target average price increase. 57.87%.
Every Jing Toutiao (nbdtoutiao)——Compromise or fight?Cross-border e-commerce sellers are trapped in the “encirclement hunting” of intellectual property
(Reporter Zhou Yuxiang)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. According to this operation, at your own risk.
Copyright Notice
1This article is the original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, extracting, copying or creating mirror images, etc., offenders must be investigated.
3Copyright cooperation telephone: 021-60900099.